Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(02): 180-181
DOI: 10.1055/s-0041-1730090
Report on International Publication

Identifying Myeloma Patients at Risk of Lenalidomide or Pomalidomide Resistance at Relapse: A New Opportunity

Suvir Singh 
1   Department of Clinical Hematology and Stem Cell Transplantation, Dayanand Medical College, Ludhiana, Punjab, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Gooding et al reported an interesting study that demonstrated the presence of acquired genetic changes in cereblon in patients with multiple myeloma refractory to lenalidomide or pomalidomide.[1] We provide a short summary and appraisal of this study and implications for clinical practice.



Publication History

Article published online:
27 July 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Gooding S, Ansari-Pour N, Towfic F. et al. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood 2021; 137 (02) 232-237
    CrossrefPubMedGoogle Scholar
  • 2 Krönke J, Udeshi ND, Narla A. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014; 343 (61/68) 301-305
    CrossrefPubMedGoogle Scholar
  • 3 Klimowicz A, Neri P, Belch A. et al. High cereblon protein expression correlates with improved response and survival in myeloma patients treated with lenalidomide. American Society of Hematology Blood 2012; 120 (21) 931
    Google Scholar
  • 4 Schuster SR, Kortuem KM, Zhu YX. et al. The clinical significance of cereblon expression in multiple myeloma. Leuk Res 2014; 38 (01) 23-28
    CrossrefPubMedGoogle Scholar
  • 5 Franssen LE, Nijhof IS, Couto S. et al. Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients. Haematologica 2018; 103 (08) e368-e371
    CrossrefPubMedGoogle Scholar
  • 6 Dimopoulos K, Fibiger Munch-Petersen H, Winther Eskelund C. et al. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma. Leuk Lymphoma 2019; 60 (01) 180-188
    CrossrefPubMedGoogle Scholar
  • 7 Thakurta A, Gandhi AK, Waldman MF. et al. Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. Leukemia 2014; 28 (05) 1129-1131
    CrossrefPubMedGoogle Scholar
  • 8 Lodé L, Amiot M, Maiga S. et al. Cereblon expression in multiple myeloma: not ready for prime time. Br J Haematol 2013; 163 (02) 282-284
    PubMedGoogle Scholar
  • 9 Qian X, Dimopoulos MA, Amatangelo M. et al. Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS. Leuk Lymphoma 2019; 60 (02) 462-470
    CrossrefPubMedGoogle Scholar
  • 10 Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J 2020; 10 (09) 94
    CrossrefPubMedGoogle Scholar
  • 11 Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood 2019; 133 (07) 660-675
    CrossrefPubMedGoogle Scholar